Status:
COMPLETED
A Study Of BRL49653C For The Treatment Of Type 2 Diabetes (Combination Therapy With Sulfonyl Urea) -With Placebo Study
Lead Sponsor:
GlaxoSmithKline
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
This study was designed to compare the efficacy and safety of BRL49653C versus placebo with concomitant use of sulfonyl urea (SU).
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients with type 2 diabetes mellitus managed by SU will be candidate for this study. These candidates will be checked up on their clinical laboratory data, and must have adequate blood, liver and kidney function.
- Exclusion criteria:
- Patient with serious cardiovascular disease or serious hepatic disease will not be eligible.
Exclusion
Key Trial Info
Start Date :
May 24 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 28 2007
Estimated Enrollment :
149 Patients enrolled
Trial Details
Trial ID
NCT00432679
Start Date
May 24 2006
End Date
March 28 2007
Last Update
December 12 2022
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Kanagawa, Japan, 212-0024
2
GSK Investigational Site
Kumamoto, Japan, 862-0976
3
GSK Investigational Site
Ōita, Japan, 870-0039
4
GSK Investigational Site